Full analysis of the main functions and indications of Pemetinib (Dabotan) tablets

Pemigatinib (Pemigatinib) is an oral small molecule targeted drug. It is a fibroblast growth factor receptor (FGFR) inhibitor. It mainly inhibits FGFR1, FGFR2 and FGFR3 signaling pathways blocks tumor cell proliferation, angiogenesis and survival signals, thereby exerting anti-tumor effects. This drug is mainly used clinically for patients with tumors carrying FGFR2 fusion or rearrangement mutations, especially patients with cholangiocarcinoma.

In terms of indications, pemetinib tablets have been approved by the FDA for the treatment of patients with advanced or metastatic cholangiocarcinoma (ICC) carrying FGFR2 fusion or rearrangement mutations, especially for cases that have progressed despite previous standard chemotherapy. This indication is based on the results of the pivotal clinical trial FIGHT-202, which showed that pemetinib can significantly improve the overall response rate (ORR) and disease control rate (DCR), providing a new option for targeted therapy for patients with advanced cholangiocarcinoma.

In clinical applications, pemetinib tablets are usually administered as daily oral doses and can be individually adjusted based on tolerance and renal and hepatic function. Serum phosphorus levels, liver function, kidney function, and eye examinations need to be monitored regularly during treatment, because common adverse reactions of FGFR inhibitors include hyperphosphatemia, fatigue, diarrhea, and abnormal vision. Timely management and dose adjustment can effectively reduce the incidence of adverse events while maintaining drug efficacy.

In general, pemetinib tablets provide precise treatment options for patients with advanced cholangiocarcinoma by targeting the FGFR signaling pathway, and are particularly suitable for patients with positive FGFR2 fusion or rearrangement. Its main advantage is that it can provide significant tumor control and response despite failure of previous chemotherapy. In clinical use, genetic testing results, drug tolerance and monitoring indicators need to be combined to formulate individualized treatment plans to achieve optimal efficacy and safety.

Keyword tags: pemetinib, FGFR inhibitor, cholangiocarcinoma, indications, adverse reactions

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf